Andreas Wallnofer Ph.D

Andreas Wallnofer Ph.D General Information

Biography

Dr. Andreas Wallnofer serves as Advisor at ClavystBio. He served as Board Member at TOLREMO therapeutics. He serves as Chairman at Nuevocor. He served as Partner at Jeito. He served as Supervisory Board Member at Ventaleon. He served as General Partner at BioMedPartners. He served as a Board Member at Azafaros and Alentis Therapeutics. He serves as Vice Chairman at Polyphor. He was a Board Member of Amal Therapeutics. He is a senior executive leader with more than 20 years of experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He led the Roche Pharma Cardiovascular & Metabolism Disease Area and left Roche in 2015 after the company strategically decided to exit these reasearch areas. At Roche, he was involved in several successful product development programs. As Head of Clinical Research & Exploratory Development, he and his groups were involved in the Due Diligence evaluations for in-licensing projects and product acquisitions. He had also a key role in the integration of the Roche and Genentech Development organizations and led subsequently Early Development and Portfolio Management at Roche. He will strengthen BioMed expertise in Pharma from discovery to regulatory filing submissions. He earned Ph.D. in Pharmacology from University of Basel in 1989, Executive MBA from IMD Business School, and M.Tech in Innovation and Leadership from IMD Business School in 2002.